Zacks: Brokerages Expect Corcept Therapeutics Incorporated (NASDAQ: CORT) to Report Earnings of $ 0.19 per Share


Stock analysts expect Corcept Therapeutics Incorporated (NASDAQ: CORT) to report earnings per share of $ 0.19 for the current quarter, according to Zacks. Two analysts have released earnings estimates for Corcept Therapeutics, with estimates ranging from $ 0.18 to $ 0.21. Corcept Therapeutics posted earnings of $ 0.17 per share in the same quarter of last year, which would indicate a positive growth rate of 11.8% year-over-year. The company is expected to release its next quarterly results on Tuesday, November 2.

According to Zacks, analysts expect Corcept Therapeutics to report annual earnings of $ 0.82 per share for the current year, with EPS estimates ranging from $ 0.77 to $ 0.88. For next year, analysts expect the company to report earnings of $ 0.97 per share, with EPS estimates ranging from $ 0.92 to $ 1.03. Zacks’ EPS calculations are an average based on a survey of sales-side research analysts who cover Corcept Therapeutics.

Corcept Therapeutics (NASDAQ: CORT) last reported its quarterly results on Thursday, July 29. The biotech company reported EPS of $ 0.21 for the quarter, beating the consensus estimate of $ 0.14 by $ 0.07. Corcept Therapeutics generated a net margin of 28.45% and a return on equity of 19.08%. The company posted revenue of $ 91.59 million in the quarter, compared to analysts’ expectations of $ 85.83 million.

A number of research companies have weighed in on CORT. HC Wainwright reaffirmed a “buy” note on shares of Corcept Therapeutics in a research report on Friday, July 30. TheStreet upped Corcept Therapeutics shares from a “c +” rating to a “b-” rating in a research report on Thursday, July 8. The UBS Group reaffirmed a “positive” rating on the shares of Corcept Therapeutics in a research report on Tuesday 22 June. Finally, Zacks Investment Research upgraded Corcept Therapeutics shares from a “sell” rating to a “keep” rating and set a price target of $ 24.00 for the company in a research report released on Wednesday. July 7.

(A d)

The explosive rise in tech stocks we saw in 2020 is just the start …

“The Earnings Whisperer” Louis Navellier posted a video detailing several key steps he believes every American should take right now.

In other news, insider Gary Charles Robb sold 47,853 shares in a trade dated Wednesday, September 15. The shares were sold at an average price of $ 20.49, for a total trade of $ 980,507.97. The sale was disclosed in a legal file with the SEC, which is available at this link. Additionally, principal Daniel N. Swisher, Jr. sold 7,500 shares in a trade dated Thursday, September 2. The stock was sold at an average price of $ 21.70, for a total trade of $ 162,750.00. As a result of the sale, the director now directly owns 7,500 shares of the company, valued at approximately $ 162,750. Disclosure of this sale can be found here. In the past ninety days, insiders have sold 136,694 shares of the company valued at $ 2,894,971. 16.50% of the shares are currently held by insiders.

Institutional investors have recently changed their positions in the company. Ameriprise Financial Inc. increased its position in Corcept Therapeutics by 5.5% in the 1st quarter. Ameriprise Financial Inc. now owns 470,555 shares of the biotech company valued at $ 11,194,000 after purchasing an additional 24,585 shares in the last quarter. UBS Group AG increased its stake in Corcept Therapeutics by 1.5% in the 1st quarter. UBS Group AG now owns 41,569 shares of the biotech company valued at $ 989,000 after purchasing an additional 621 shares in the last quarter. Principal Financial Group Inc. increased its stake in Corcept Therapeutics by 0.3% in the 1st quarter. Principal Financial Group Inc. now owns 746,416 shares of the biotech company valued at $ 17,757,000 after purchasing an additional 2,400 shares during the period. Burney Co. increased its stake in Corcept Therapeutics by 2.3% in the 2nd quarter. Burney Co. now owns 386,608 shares of the biotech company valued at $ 8,506,000 after purchasing an additional 8,781 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Corcept Therapeutics by 4.1% in the second quarter. Victory Capital Management Inc. now owns 53,489 shares of the biotech company valued at $ 1,176,000 after purchasing an additional 2,093 shares during the period. Institutional investors hold 68.64% of the shares of the company.

CORT shares traded down $ 0.12 during trading hours on Friday, reaching $ 20.51. The stock had a trade volume of 2,000,802 shares, compared to its average volume of 556,771. The company has a 50-day moving average price of $ 20.92 and a 200-day moving average price of 22. $ 17. Corcept Therapeutics has a 52 week low of $ 16.42 and a 52 week high of $ 31.18. The company has a market cap of $ 2.38 billion, a price / earnings ratio of 26.99, a PEG ratio of 1.80, and a beta of 0.69.

About Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company engaged in the discovery, development and commercialization of drugs to treat serious metabolic, oncological and psychiatric disorders. He is focusing on drug development for disorders associated with a steroid hormone called cortisol.

Further reading: Mutual funds are not immune to market timing

Get a Free Copy of Zacks’ Research Report on Corcept Therapeutics (CORT)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Corcept Therapeutics Revenue History and Estimates (NASDAQ: CORT)

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Corcept Therapeutics now?

Before you consider Corcept Therapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the larger market takes hold of … and Corcept Therapeutics was not on the list.

Although Corcept Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bids.

See the 5 actions here


Comments are closed.